SARVARI YELLAPRAGADA to Treatment Outcome
This is a "connection" page, showing publications SARVARI YELLAPRAGADA has written about Treatment Outcome.
Connection Strength
0.160
-
Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? JAMA Oncol. 2021 10 01; 7(10):1449-1450.
Score: 0.063
-
HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):e143-e146.
Score: 0.048
-
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clin Lymphoma Myeloma Leuk. 2024 08; 24(8):523-530.
Score: 0.019
-
Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother. 2018 Oct; 41(8):379-383.
Score: 0.013
-
Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors. Br J Haematol. 2017 04; 177(1):142-144.
Score: 0.011
-
Hypomethylating agents for urologic cancers. Future Oncol. 2011 Mar; 7(3):447-63.
Score: 0.008